Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status approved; investigational
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 0074-1658; 0074-4637; 0074-9036; 0143-9624; 65162-823; 65862-936; 70121-1035; 43598-565; 55150-213; 67457-379; 66499-0019; 16729-311; 43598-562; 55150-215; 68382-331; 65862-938; 67457-692; 69452-147; 10888-8103; 10888-8104; 11014-0334; 48943-0033; 58032-1001; 68513-1054; 49483-689; 55150-212; 68382-330; 69452-145; 70121-1033; 70121-1034; 10888-8102; 14474-021; 0143-9625; 49483-687; 65862-937; 11014-0048; 55111-663; 70121-1036; 58272-192; 0074-9037; 43598-563; 49483-688; 55111-665; 63629-2452; 67457-380; 16729-310; 25000-017; 0143-9596; 55150-214; 63629-2453; 65162-822; 67457-389; 69452-146; 25000-014; 43598-564; 55111-664; 65162-824; 11014-0053; 25000-012
UNII 6702D36OG5
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stupor17.02.04.007; 19.02.05.004---
Sudden death02.03.04.013; 08.04.01.0030.030412%
Swelling08.01.03.015---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tension19.06.02.005---
Thirst08.01.09.021; 14.03.02.007---
Unresponsive to stimuli17.02.05.031---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Uterine cancer16.12.05.001; 21.07.02.0030.002943%-
Vaginal infection11.01.10.002; 21.14.02.002--
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Myocardial haemorrhage02.04.02.018; 24.07.01.0350.002943%-
Ischaemic cardiomyopathy02.04.01.004; 24.04.04.0190.007848%-
Brain death08.04.01.004; 17.02.03.0030.002943%-
Sudden cardiac death02.03.04.016; 08.04.01.0080.001962%-
Tachyarrhythmia02.03.02.0080.002943%-
Cardiac death02.03.04.015; 08.04.01.0070.001962%-
Cardiopulmonary failure02.05.01.004; 22.02.06.0040.002943%-
Calciphylaxis14.04.01.0120.003924%-
Haemodynamic instability24.03.02.0060.003924%-
Ear discomfort04.03.01.005---
Respiratory tract congestion22.02.07.0030.001962%-
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene